Reference
-
EVRENZO gets patients to target1
EVRENZO gets non-dialysis-dependent patients to target – and keeps them there1
Patients treated with EVRENZO reached target Hb levels and remained within the target range1
Hb, haemoglobin; DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; NDD, non-dialysis-dependent; SE, standard error.
- EVRENZO SmPC.
-
EVRENZO efficacy was comparable with ESA1,2
The Phase Ill DOLOMITES study evaluated the efficacy and safety profile of EVRENZO compared to darbepoetin-alfa for the treatment of anaemia in NDD patients with stage 3-5 CKD. In the primary endpoint analysis, the study demonstrated non-inferiority of EVRENZO to darbepoetin-alfa in the proportion of patients achieving correction of Hb levels during the first 24 weeks of treatment (89.5% vs. 78%, respectively)2
CKD, chronic kidney disease; DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; EOT, end of treatment; Hb, haemoglobin; IDD, incident dialysis-dependent; NDD, non-dialysis-dependent.
Reference
- EVRENZO SmPC.
- Barratt J et al. Nephrol Dial Transplant. 2021;36(9):1616–1628.
-
EVRENZO reduced use of IV iron1,2
CKD, chronic kidney disease; DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent. IV, intravenous; IDD, incident dialysis-dependent; NDD, non-dialysis-dependent.
References
- EVRENZO SmPC.
- Barratt J et al. Nephrol Dial Transplant. 2021;36(9):1616–1628.
-
EVRENZO summary in NDD
In non-dialysis-dependent CKD, EVRENZO can help your patients meet and maintain their Hb targets1
Hb correction and maintenance was statistically superior to placebo (p<0.0001) and comparable with ESA (p=0.844)1,2
EVRENZO treatment reduced the use of IV iron supplementation compared with treatment with ESA1,2
CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; IV, intravenous.
Reference
- EVRENZO SmPC.
- Barratt J et al. Nephrol Dial Transplant. 2021;36(9):1616–1628.